Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials

Bibliography

• CDC 2010 National Diabetes Fact Sheet. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Last accessed 10 March 2011
   Google Scholar
• Ligaray KPL, Isley WL. Diabetes mellitus, type 2. Available from: http://emedicine.medscape.com/article/117853-overview. Last accessed 26 January 2011
   Google Scholar
• Doggrell SA. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Rev Recent Clin Trials 2007;2:77-84
   PubMedGoogle Scholar
• Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009;124:113-38
   PubMed Web of Science ®Google Scholar
• Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123(3 Suppl):S26-37
   Google Scholar
• Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57
   PubMed Web of Science ®Google Scholar
• Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-24
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P, Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248
   Web of Science ®Google Scholar
• Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 201;16(7 Suppl):S187-94
   Google Scholar
• Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2008;67:935-54
   Web of Science ®Google Scholar
• Barnett A. Exenatide. Expert Opin Pharmacother 2007;8:2593-608
   PubMed Web of Science ®Google Scholar
• Guerci B, Martin CS. Exenatide: its position in the treatment of type 2 diabetes. Ann Endocrinol (Paris) 2008;69:201-9
   PubMed Web of Science ®Google Scholar
• Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab 2009;11:544-6
   PubMed Web of Science ®Google Scholar
• Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med 2009;26:837-46
   PubMed Web of Science ®Google Scholar
• Malone J, Trautmann M, Wilhelm K, Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009;18:359-67
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, MacConell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2); a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Beconi M, (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazole[4,3-a]pyrazin-7(8H)-1-(2,4,5-trifluorphenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, Pharmacokinetics and pharmacodynamics of sitagliptin, and inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two-randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Stevens C, Zhou Y, Pharmacokinetics and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, or incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Herman GA, Wu M, Once-daily sitagliptin, a dipeptidyl pertidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-39
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu C, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
   PubMed Web of Science ®Google Scholar
• Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002;32(Suppl 3):35-45
   PubMedGoogle Scholar
• Aschner P, Kipnes MS, Lunceford JK, Effect of the dipeptidyl peptidate-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
   PubMed Web of Science ®Google Scholar
• Nonaka K, Kakisawa T, Sato A, Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-8
   PubMed Web of Science ®Google Scholar
• Mohan V, Yang W, Son HY, Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106-16
   PubMed Web of Science ®Google Scholar
• Aschner P, Katzeff HL, Guo H, Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61
   PubMed Web of Science ®Google Scholar
• Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Tajima N, Kadowaki T, Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;17:613-22
   Google Scholar
• Bosi E. Metformin – the gold standard in type 2 diabetes: what does the evidence tell us?. Diabetes Obes Metab 2009;11(Suppl 2):3-8
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Yi B, Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-47
   PubMed Web of Science ®Google Scholar
• Aaboe K, Knopp FK, Visboll T, Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:323-33
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: 54-week study. Curr Med Res Opin 2009;25:569-83
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-51
   PubMed Web of Science ®Google Scholar
• Migoya EM, Miller JL, Gutierrez M, Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. Clin Drug Invest 2010;30:855-66
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
   PubMed Web of Science ®Google Scholar
• Seck T, Nauck M, Sheng D, Safety and efficacy of sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-78
   PubMed Web of Science ®Google Scholar
• Arechavaleta R, Seck T, Chen Y, Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-8
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Rigby SP, Handelsman Y, Lai Y-L, Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract 2010;16:53-63
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-9
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
   PubMed Web of Science ®Google Scholar
• Misty GC, Bergman AJ, Zheng W, Sitagliptin, an dipeptidyl peptidase-4-inhibitor, does not alter the pharmacokinetics of the sulponylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008;66:36-42
   PubMed Web of Science ®Google Scholar
• De Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther 2010;8:1057-67
   PubMedGoogle Scholar
• Rosenstock J, Brazq R, Andryuk PJ, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;28:1556-68
   Web of Science ®Google Scholar
• Derosa G, Maffoli P, Salvadeo SA, Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
   PubMed Web of Science ®Google Scholar
• Vishøll T, Rosenstock J, Uki-Jarvinen H, Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
   PubMedGoogle Scholar
• Sudhakaran C, Kishore U, Anjana RM, Effectiveness of sitagliptin in Asian Indian patients with type 2 diabetes – an Indian tertiary diabetes care center experience. Diabetes Technol Ther 2011;13:27-32
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Smith P, Prickett KS, Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005;48:1380-5
   PubMed Web of Science ®Google Scholar
• Fineman M, Flanagan S, Taylor K, Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Nasu R, Yamamura A, Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009;56:951-62
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhang D, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Buse JB, Druker DJ, Taylor KL, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Best JH, Boye KE, Rubin RR, Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009;26:722-8
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-52
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH, Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies; a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin – a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
   PubMed Web of Science ®Google Scholar